Enveric 10-Q: Going Concern Warning, $5.6M Cash, Material Weaknesses Disclosed
ENVB sits 29% above its 52-week low of $1.17 on light trading volume (0.2× avg).
Summary
Enveric's Q3 10-Q discloses substantial going-concern doubt, with $5.6M of cash against a $7.4M nine-month operating burn, plus ineffective disclosure controls tied to material weaknesses. New financing is needed to fund EB-003 through an IND filing.
Key Events · Earnings and Guidance · ENVB
-
Going Concern Doubt Disclosed
Management states substantial doubt about the company's ability to continue as a going concern for one year from issuance, with $5,612,988 of cash at September 30, 2026 insufficient to satisfy operating cash needs for the 12 months following the filing.
-
Nine-Month Cash Burn of $7.4M
Operating cash outflow was $7,352,346 and the loss from operations was $7,224,699 for the nine months ended September 30, 2026; the accumulated deficit reached $122,057,052.
-
Disclosure Controls Not Effective
The CEO and CFO concluded disclosure controls and procedures were not effective as of September 30, 2026 in light of material weaknesses in internal control over financial reporting previously disclosed in the 2025 10-K.
-
Share Count Up on Prior Raises
Shares outstanding rose to 4,475,884 from 1,061,533 at December 31, 2025 after the January and April 2026 offerings, ATM sales of 497,200 shares for $1,291,038 net, and warrant exercises; 5,853,318 warrants remain outstanding at a $4.98 weighted average exercise price.
Analysis · ENVB · Life Sciences
The Q3 10-Q formalizes what the same-day 8-K only summarized. Management states substantial doubt about Enveric's ability to continue as a going concern for one year, with $5,612,988 of cash at September 30, 2026 insufficient to fund the next 12 months of operations. Over nine months the company burned $7,352,346 in operating cash and carries a $122,057,052 accumulated deficit, so another equity raise is effectively required — and prior raises already expanded shares outstanding from 1,061,533 at December 31, 2025 to 4,475,884. The filing also concludes disclosure controls were not effective as of September 30, 2026 because of previously disclosed material weaknesses, a governance overhang on top of the funding need. The one offset is pipeline progress: EB-003 IND-enabling ADMET and qEEG work advanced, and a third U.S. patent allowance came in for the EVM401 Series, but no IND submission date is given.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENVB was trading at $1.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.8M. The 52-week trading range was $1.17 to $13.25. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.